陈进进副研究员
中山大学孙逸仙纪念医院基础与转化医学研究中心
联系方式:chenjj365@mail.sysu.edu.cn,个人简介,中山大学孙逸仙纪念医院青年研究员,博士生导师。获得国家优秀青年基金(海外)资助,是国家重点研发计划(青年科学家)项目负责人。兼任广东省抗癌协会纳米肿瘤分会常务委员。应邀担任Chinese Chemical Letters,Exploration,Asian J. Pharm. Sci.等杂志青年编委,现在主要研究方向为:mRNA的递送与应用(mRNA疫苗、基因编辑、蛋白替代疗法等)。目前已在Science Advances,Advanced Materials,PNAS,Nano Letters,Angew. Chem. Int. Ed.,Nano Today 等学术期刊发表论文30余篇,3篇论文分别入选ESI热点与高被引论文。以共同发明人授权/申请专利9项。教育经历,2008/09-2012/07 中国科学技术大学 学士,2012/09-2018/1 中国科学院大学,长春应用化学研究所 博士 导师:陈学思 院士,工作经历,2018/4-2021/10 塔夫茨大学 生物医学工程系 博士后 合作导师:许巧兵 教授,2021/12-至今中山大学 孙逸仙纪念医院 青年研究员、博士生导师,承担项目:1.“十四五”国家重点研发计划,青年科学家项目,主持,2023.11-2026.10,300万;2.国家自然科学基金优秀青年科学基金(海外),主持,2023.1-2025.12,200 万;3.国家自然科学基金,面上项目,主持,2025.1-2028.12,48万;4.广东省高层次人才项目,主持,2024.1-2025.12,50万;5.广州市科技菁英“领航“,主持,2024.1-2026.12,30万;6.中山大学,高校基本科研业务费,主持,2022.1-2024.12,100万;7.中山大学“百人计划“启动经费,主持,2022.1-2024.12,200万,著作、论文、成果:代表性论著 (#共同一作,*通讯作者),(1) Qian Shen#,Jia Liu#,Ling Zeng,Yupeng Ren,Jing Liao,Sijie Chen,Yingsen Tang,Zixi Zhang,Meng Jiang,Hangping Liao,Lingyun Wang*,Xiaoding Xu*,Jinjin Chen*,Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma,Journal of Controlled Release,2025,381,113588,(IF=10.5).,(2) Chipeng Guo,Yingsen Tang,Ling Zeng,Xiaomei You,Siweier Luo,Yufei Du,Le Wang,Liangchun Wang,Jianchuan Wang*,Jinjin Chen*,Yiming Zhou*,Therapeutic Potential of Lipid Nanoparticle‐Encapsulated CD19‐Targeting mRNAs in Lupus and Rheumatoid Arthritis,Advanced Science,2025,2501628,(IF=14.3).,(3) Xinrou Lin,Lingyu Wei,Xiangpen Li,Ling Zeng,Yingsen Tang,Hongjin Wang,Hengjian Lu,Chenguang Li,Hongxuan Wang,Jinjin Chen*,Ying Peng*,Pia Mater‐Penetrable Lipopolymer Nanoparticles for Gliocyte‐Targeted IL‐10 mRNA Therapy Alleviate Paclitaxel‐Induced Peripheral Neuropathy,Advanced Science,2025,2500362,(IF=14.3).,(4) Jinjin Chen#,Zhongfeng Ye#,Changfeng Huang,Min Qiu,Donghui Song,Yamin Li,Qiaobing Xu*. Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proceedings of the National Academy of Sciences,2022,119(34): e2207841119 (IF=12.779).,(5) Jinjin Chen#; Min Qiu#; Zhongfeng Ye; Thomas Nyalile; Yamin Li; Zachary Glass; Xuewei Zhao; Liu Yang; Jianzhu Chen; Qiaobing Xu*; In Situ Cancer Vaccination Using Lipidoid Nanoparticles,Science Advances,2021,7: eabf1244 (IF=14.957).,(6) Jinjin Chen; Min Qiu; Feihe Ma; Liu Yang; Zachary Glass; Qiaobing Xu ; Enhanced Protein Degradation by Intracellular Delivery of Pre-Fused PROTACs Using Lipid-Like Nanoparticles,Journal of Controlled Release,2021,330(10): 1244-1249 (IF=11.467).,(7) Jinjin Chen; Jianxun Ding*; Yucai Wang; Jianjun Cheng*; Shengxiang ji; Xiuli Zhuang; Xuesi Chen*; Sequentially Responsive Shell-Stacked Nanoparticles for Deep Penetration into Solid Tumors,Advanced Materials,2017,32(29): 1701170 (IF=32.086).,(8) Jinjin Chen#; Zhongyu Jiang#; Weiguo Xu; Tianmeng Sun; Xiuli Zhuang; Jianxun Ding*; Xuesi Chen*; Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature,Nano Letters,2020,20(8): 6191-6198 (IF=12.262).,(9) Jinjin Chen#; Jianxun Ding#; Weiguo Xu; Tianmeng Sun; Haihua Xiao; Xiuli Zhuang; Xuesi Chen*; Receptor and Microenvironment Dual-Recognizable Nanogel for Targeted Chemotherapy of Highly Metastatic Malignancy,Nano Letters,2017,7(17): 4526-4533 (IF=12.262).,(10) Xuewei Zhao#; Jinjin Chen#; Min Qiu; Yamin Li; Zachary Glass; Qiaobing Xu*; Imidazole‐based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes,Angewandte Chemie International Edition,2020,59(45): 20083-20089 (IF=16.823) .,(11)Min Qiu#; Yan Tang#*; Jinjin Chen#; Rachel Muriph; Zhongfeng Ye; Changfeng Huang; Jason Evans; Elizabeth P. Henske; Qiaobing Xu*,Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis,Proceedings of the National Academy of Sciences,2022,119(8): e2116271119 (IF = 12.779).